Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioids

FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller

Natalie Grover & Toni Clarke  |  June 8, 2016

(Reuters)—A U.S. Food and Drug Administration (FDA) advisory panel recommended approving Teva Pharmaceuticals Industries Ltd’s long-acting opioid painkiller, Vantrela ER, saying data showed it reduces pain and has some abuse-resistant properties. The drug is designed for use every 12 hours for the management of pain severe enough to require around-the-clock treatment in patients who have…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painFDAFood and Drug AdministrationOpioidsTeva Pharmaceuticals

U.S. FDA Approves First-Ever Implant to Treat Opioid Addiction

Natalie Grover  |  May 27, 2016

(Reuters)—The first-ever implant to fight addiction to opioids, a class of drugs that includes prescription painkillers and heroin, was approved by the U.S. Food and Drug Administration on Thursday. The matchstick-sized implant, developed by Titan Pharmaceuticals Inc. and privately owned Braeburn Pharmaceuticals, is by design less susceptible to abuse or the illicit resale that plagues…

Filed under:AnalgesicsDrug Updates Tagged with:AddictionbuprenorphineimplantOpioidsPainPain Management

Technological Advances Linked to Medical Misadventures

Simon M. Helfgott, MD  |  April 15, 2016

For keen students of American politics, the unending intrigue of the 2016 presidential race has been riveting. With an assemblage of aspiring candidates that, at its start, included a bevy of U.S. senators and former governors, a media-savvy real estate mogul, a renowned Hopkins neurosurgeon and an ophthalmologist, political junkies among us have feasted on…

Filed under:OpinionPractice SupportQuality Assurance/ImprovementRheuminationsSpeak Out RheumTechnology Tagged with:dataEHRelectronic health recordmedical errorphysicianPractice ManagementQualityrheumatologistTechnology

2015 ACR/ARHP Annual Meeting: Better Pain Prevention, Treatment Needed for Older Adults

Thomas R. Collins  |  April 14, 2016

SAN FRANCISCO—A broadening of the medical community’s horizons in how pain is regarded and treated in older adults, including those with osteoarthritis and other rheumatic diseases, is sorely needed, a researcher said at the 2015 ACR/ARHP Annual Meeting. Incidence Studies show that a large percentage of older adults each year see physicians for such issues…

Filed under:ConditionsMeeting ReportsPractice Support Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)elderlyolderPainpatient carePractice ManagementpreventionrheumatologistseniorTreatment

Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use

Anne Harding  |  March 30, 2016

NEW YORK (Reuters Health)—Medical cannabis reduces chronic pain patients’ opioid use, while improving their quality of life, according to a new survey of Michigan cannabis dispensary patrons. “They report that when they make that switch they overall feel better,” Dr. Daniel J. Clauw of the University of Michigan, Ann Arbor, told Reuters Health in a…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:AddictioncannabisChronic painmarijuanaOpioidsPainPain Management

FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers

Reuters Staff  |  March 23, 2016

(Reuters)—The U.S. Food and Drug Administration announced on Tuesday new required class-wide safety labeling changes for immediate-release opioid pain medications. Among the changes, the FDA now requires these pain medications to carry a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. The FDA also requires several additional safety labeling…

Filed under:AnalgesicsDrug Updates Tagged with:FDAFood and Drug AdministrationGuidelinesOpioidsOverdose

Trying to Parse True Meaning of Pain Can be Challenging for Rheumatologists

Trying to Parse True Meaning of Pain Can Be Challenging for Rheumatologists

Simon M. Helfgott, MD  |  March 15, 2016

Discussing aching joints, sore muscles and tender limbs is all in our day’s work. We are rheumatologists; we deal in misery. But trying to parse the true meaning of these terms is among the most vexing of clinical challenges.

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:DiagnosisPainpatient carerheumatologistrheumatologyswelling

U.S. Senate Moves Closer to Confirming Califf to Lead FDA

Toni Clarke  |  February 24, 2016

WASHINGTON (Reuters)—The U.S. Senate on Monday moved closer to confirming Dr. Robert Califf to lead the U.S. Food and Drug Administration, overriding opposition from several senators who had sought to block a vote on the issue. In a procedural move designed to prevent the opponents from blocking the confirmation indefinitely, the Senate voted 80 to…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:FDAFood and Drug AdministrationRegulation

Rheumatologist, Pain Physician Collaboration Vital for Better Pain Control

Vanessa Caceres  |  February 17, 2016

Chronic pain can be one of the biggest challenges that patients and their physicians face. Rheumatology patients are no stranger to pain, and when pain goes beyond the scope of what rheumatologists can treat, collaboration with a pain specialist is common. “I refer patients to pain management when there is no underlying inflammatory condition, usual…

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:PainPain Managementpain specialistpatient carerheumatologistTreatment

2015 ACR/ARHP Annual Meeting: How Gender Differences Affect Pain

Thomas R. Collins  |  February 16, 2016

SAN FRANCISCO—Men and women have different mechanisms that are at work in producing pain in rheumatic diseases—a little-studied and little-appreciated fact that is crucial to developing and using the right kinds of treatments, an expert in rheumatic disease pain said in a talk at the 2015 ACR/ARHP Annual Meeting. The lack of acknowledgment of this…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)GenderPainResearchRheumatic Diseaserheumatology

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 20
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences